| PUBLICATIONS |
| 1 |
Moneta D, Geroni C, Valota O, Grossi P, de
Jonge MJA; Brughera M et al. (2003). Predicting the maximum-tolerated
dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'- methylsulphonyl-daunorubicin)
in humans using CFU-GM clonogenic assays and prospective validation.
EurJ of Cancer 39(5), 675-683. |
| 2 |
de Kanter R, Monshouwer N, Meijer D, Groothuis
G (2002). Precision-cut organ slices as a tool to study toxicity
and metabolism of xenobiotics with specialreference to non-hepatic
tissues. Curr Drug Metab. 3(1):39-59. Review. |
| 3 |
Della Torre P, Podesta A, Imondi AR, Moneta
D, Sammartini U, Arrigoni C, Terron A, Brughera M (2001). PNU-159548,
a novel cytotoxic antitumor agent with a low cardiotoxic potential.
Cancer Chemother and Pharmacol 47(4), 355-60. |
| 4 |
Colombo P, Gunnarsson K, Iatropoulos M, Brughera
M (2001). Toxicological testing of cytotoxic drugs (Review). Int
J of Oncol 19(5), 1021-1028. |
| 5 |
Beltrame D, di Salle E, Giavini E, Gunnarsson
K, Brughera M (2001). Reproductive toxicity of exemestane, an antitumoral
aromatase inactivator, in rats and rabbits. Reproductive Toxicology
15(2), 195-213. |
|